EMBO Molecular Medicine (Oct 2020)

MYH3‐associated distal arthrogryposis zebrafish model is normalized with para‐aminoblebbistatin

  • Julia Whittle,
  • Lilian Antunes,
  • Mya Harris,
  • Zachary Upshaw,
  • Diane S Sepich,
  • Aaron N Johnson,
  • Mayssa Mokalled,
  • Lilianna Solnica‐Krezel,
  • Matthew B Dobbs,
  • Christina A Gurnett

DOI
https://doi.org/10.15252/emmm.202012356
Journal volume & issue
Vol. 12, no. 11
pp. 1 – 14

Abstract

Read online

Abstract Distal arthrogryposis (DA) is group of syndromes characterized by congenital joint contractures. Treatment development is hindered by the lack of vertebrate models. Here, we describe a zebrafish model in which a common MYH3 missense mutation (R672H) was introduced into the orthologous zebrafish gene smyhc1 (slow myosin heavy chain 1) (R673H). We simultaneously created a smyhc1 null allele (smyhc1−), which allowed us to compare the effects of both mutant alleles on muscle and bone development, and model the closely related disorder, spondylocarpotarsal synostosis syndrome. Heterozygous smyhc1R673H/+ embryos developed notochord kinks that progressed to scoliosis with vertebral fusions; motor deficits accompanied the disorganized and shortened slow‐twitch skeletal muscle myofibers. Increased dosage of the mutant allele in both homozygous smyhc1R673H/R673H and transheterozygous smyhc1R673H/− embryos exacerbated the notochord and muscle abnormalities, causing early lethality. Treatment of smyhc1R673H/R673H embryos with the myosin ATPase inhibitor, para‐aminoblebbistatin, which decreases actin–myosin affinity, normalized the notochord phenotype. Our zebrafish model of MYH3‐associated DA2A provides insight into pathogenic mechanisms and suggests a beneficial therapeutic role for myosin inhibitors in treating disabling contractures.

Keywords